Literature DB >> 18827739

Expression of cyclooxygenase-2 in choroidal neovascular membranes from age-related macular degeneration patients.

Shawn C Maloney1, Bruno F Fernandes, Enzo Castiglione, Emilia Antecka, Claudia Martins, Jean-Claude Marshall, Sebastian Di Cesare, Patrick Logan, Miguel N Burnier.   

Abstract

PURPOSE: The objective of this study was to investigate the expression of cyclooxygenase (COX)-2 in human choroidal neovascular membranes.
METHODS: Paraffin-embedded sections of choroidal neovascular membranes excised from 16 patients with wet age-related macular degeneration were used for this study. Sections were subjected to immunohistochemistry using a monoclonal mouse antihuman COX-2 antibody. Staining was classified as either negative or positive in retinal pigment epithelial cells, vascular endothelial cells, and fibroblasts. Serial sections were stained for vimentin expression to confirm tissue antigenicity.
RESULTS: Eleven of 16 (69%) choroidal neovascular membranes stained positive for COX-2 in retinal pigment epithelial cells, with 6 (38%) of these also expressing COX-2 in vascular endothelial cells and 6 (38%) in fibroblasts. None of the sections that were negative for COX-2 in the retinal pigment epithelial cells showed COX-2 expression in the other cell types assessed. There was a statistically significant difference (P = 0.0097) in the mean ages between the COX-2 positive group (65.6 years) and COX-2 negative group (76.8 years) as determined by a two-tailed, unpaired Student's t-test.
CONCLUSION: The expression of COX-2 in human choroidal neovascular membranes suggests a possible role for this modulator in age-related macular degeneration pathogenesis. The age-dependent expression observed is novel and warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18827739     DOI: 10.1097/IAE.0b013e3181884fa6

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  16 in total

1.  The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment.

Authors:  Y Wang; V M Wang; C-C Chan
Journal:  Eye (Lond)       Date:  2010-12-24       Impact factor: 3.775

2.  The safety, pharmacokinetics, and efficacy of intraocular celecoxib.

Authors:  Stephen J Kim; Hassanain Toma; Rohan Shah; Uday B Kompella; Sunil K Vooturi; Jinsong Sheng
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-10       Impact factor: 4.799

3.  Expression of cyclooxygenases and trophic and growth factors in epiretinal membranes at late stages of proliferative vitreoretinopathy.

Authors:  Marina Tikhonovich; Pavel Lyskin; Elena Ioyleva; Svetlana Gavrilova
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-08-02       Impact factor: 3.117

4.  Ketorolac inhibits choroidal neovascularization by suppression of retinal VEGF.

Authors:  Stephen J Kim; Hassanain S Toma; Joshua M Barnett; John S Penn
Journal:  Exp Eye Res       Date:  2010-07-24       Impact factor: 3.467

5.  Reduced choroidal neovascular membrane formation in cyclooxygenase-2 null mice.

Authors:  Kasra A Rezaei; Hassanain S Toma; Jiyang Cai; John S Penn; Paul Sternberg; Stephen J Kim
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-02-03       Impact factor: 4.799

6.  Fluorocoxib A enables targeted detection of cyclooxygenase-2 in laser-induced choroidal neovascularization.

Authors:  Md Jashim Uddin; Chauca E Moore; Brenda C Crews; Cristina K Daniel; Kebreab Ghebreselasie; J Oliver McIntyre; Lawrence J Marnett; Ashwath Jayagopal
Journal:  J Biomed Opt       Date:  2016-09-01       Impact factor: 3.170

7.  Critical appraisal of ophthalmic ketorolac in treatment of pain and inflammation following cataract surgery.

Authors:  Rahul Reddy; Stephen Jae Kim
Journal:  Clin Ophthalmol       Date:  2011-06-03

8.  Protective effects of resveratrol against UVA-induced damage in ARPE19 cells.

Authors:  Chi-Ming Chan; Cheng-Hua Huang; Hsin-Ju Li; Chien-Yu Hsiao; Ching-Chieh Su; Pei-Lan Lee; Chi-Feng Hung
Journal:  Int J Mol Sci       Date:  2015-03-12       Impact factor: 5.923

9.  Nonsteroidal anti-inflammatory drugs for retinal disease.

Authors:  Scott D Schoenberger; Stephen J Kim
Journal:  Int J Inflam       Date:  2013-01-14

Review 10.  Topical nonsteroidal anti-inflammatory drugs for macular edema.

Authors:  Andrea Russo; Ciro Costagliola; Luisa Delcassi; Francesco Parmeggiani; Mario R Romano; Roberto Dell'Omo; Francesco Semeraro
Journal:  Mediators Inflamm       Date:  2013-10-21       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.